Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure

Journal of Urology

Volumn 159, Issue 2, 1998, Pages 591-598

  Deweese, Theodore L ^a   Shipman, Jennifer M ^a   Dillehay, Larry E ^a   Nelson, William G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cell cycle checkpoints; Low dose rate radiation; Prostate cancer

Indexed keywords

IODINE 125; PROTEIN P53; STRONTIUM 89;

ARTICLE; BRACHYTHERAPY; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CONTROL; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; HUMAN; HUMAN CELL; LOW ENERGY RADIATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY;

EID: 0031984669     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63990-9     Document Type: Article

References (52)

1. Freedman, G. M., Hanks, A. L., Lee, W. R. and Hanks, G. E.: Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int. J. Rad. Oncol. Biol. Phys., 35: 243, 1996.
2. Leibel, S. A., Heimann, R., Kutcher, G. J., Zelefsky, M. J., Burman, C. M., Melian, E., Orazem, J. P., Mohan, R., LoSasso, T. J., Lo, Y.-C., Wiseberg, J. A., Chapman, D. S., Ling, C. C. and Fuks, Z.: Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study. Int. J. Rad. Oncol. Biol. Phys., 28: 55, 1994.
3. Forman, J. D., Duclos, M., Shamsa, F., Porter, A. T. and Orten, C.: Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study. Int. J. Rad. Oncol. Biol. Phys., 34: 655, 1996.
4. Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., Sathyanarayan, J. R., Yakemchuk, V. N., Thomas, G. M., Ehrlich, L. E., Crook, J., Gulenchyn, K. Y., Hong, K. E., Wesolowski, C. and Yardley, J.: Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local filed external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 25: 805, 1993.
5. 2 prostatic carcinoma. J. Clin. Oncol., 14: 449, 1996.
6. Malaise, E. P., Fertil, B., Chavaudra, N. and Guichard, M.: Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro and in vivo data. Int. J. Rad. Oncol. Biol. Phys., 12: 617, 1996.
7. Steel, G. G.: Cellular sensitivity to low dose-rate irradiation focuses the problem of tumor radioresistance. Radiother. Oncol., 20: 71, 1991.
8. Hartwell, L. H. and Kastan, M. B.: Cell cycle control and cancer. Science, 266: 1821, 1994.
9. Leeper, D. B., Schneiderman, M. H. and Dewey, W. C.: Radiation-induced cycle delay in synchronized Chinese hamster cells: comparison between DNA synthesis and division. Radiation Res., 53: 326, 1973.
10. Tolmach, L. J., Jones, R. W. and Busse, P. M.: The action of caffeine on X-irradiated HeLa cells. I. Delayed inhibition of DNA synthesis. Radiation Res., 71: 653, 1977.
11. Sinclair, W. K.: Cyclic X-ray responses in mammalian cells in vitro. Radiation Res., 33: 620, 1968.
12. Sinclair, W. K. and Morton, R. A.: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiation Res., 29: 450, 1966.
13. Kal, H. B., Barendsen, G. W., Bakker-van Haue, R. and Roeke, H.: Increased radiosensitivity of rat rhabdomyosarcoma cells induced by protracted irradiation. Radiation Res., 63: 521, 1975.
14. Mitchell, J. B., Bedford, J. S. and Bailey, S. M.: Dose-rate effects in mammalian cells in culture. III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Radiation Res., 79: 537, 1979.
15. Bedford, J. S.; Mitchell, J. B.; Fox, M. H.: Variations in responses of several mammalian cell lines to low dose-rate irradiation. In: Radiation Biology in Cancer Research. Edited by R. E. Meyn and R. Withers. New York: Raven Press, pp. 241-262, 1980.
16. Fowler, J. F.: Radiobiological aspects of low dose rate in radioimmunotherapy. Int. J. Radiation Oncol. Biol. Phys., 18: 1261, 1990.
17. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. W.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304, 1991.
18. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, B. S., Plunkett, B. S., Vogelstein, B. and Fornace, A. J.: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587, 1992.
19. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L. and Cho, K. R.: Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988, 1993.
20. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V. and Kastan, M. B.: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491, 1992.
21. Nelson, W. G. and Kastan, M. B.: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815, 1994.
22. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675, 1995.
23. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. and Vogelstein, B.: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54: 1169, 1994.
24. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B.: WAF-1, a potential mediator of p53 tumor suppression. Cell, 75: 817, 1993.
25. DeWeese, T. L., Walsh, J. C., Dillehay, L. E., Kessis, T. D., Hedrick, L., Cho, K. R. and Nelson, W. G.: Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. Int. J. Radiation Oncol. Biol. Phys., 37: 145, 1997.
26. Isaacs, W. B., Carter, B. S. and Ewing, C. M.: Wild-type p53 suppresses growth human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716, 1991.
27. Bookstein, R., Rio, P., Madreperla, S. A., Hong, F., Allred, C., Grizzle, W. E. and Lee, W.-H.: Promoter deletion and loss of retinboblastoma gene expression in human prostate carcinoma. Proc. Natl. Acad. Sci. USA, 87: 7762, 1990.
28. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L, Palmer, J. L., Nichols, W. W., Von Eschenbach, A. C. and Conti, C. J.: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
29. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I. and Isaacs, W. B.: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814, 1996.
30. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H. and Paulson, D. F.: Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer, 21: 274, 1978.
31. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F. and Jones, L. W.: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17: 16, 1979.
32. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A. and Murphy, G. P.: LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809, 1983.
33. Iizumi, T., Yazaki, T., Kanoh, S., Kondo, I. and Koiso, K.: Establishment of a new prostatic carcinoma cell line (Tsu-Pr1). J. Urol., 137: 1304, 1987.
34. Brothman, A. R., Lesho, L. J., Somers, K. D., Wright, G. L. and Merchant, D. J.: Phenotypic and cytogenetic characterization of a cell line derived from a primary prostate carcinoma. Int. J. Cancer, 44: 898, 1989.
35. Leith, J. T.: In vitro radiation sensitivity of the LNCaP prostate cell line. Prostate, 24: 119, 1994.
36. Leith, J. T., Quaranto, L., Padfield, G., Michelson, S. and Hercbergs, A.: Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray senstitivity in vitro and hypoxic fractions of xenografted tumors in vivo. Int. J. Rad. Oncol. Biol. Phys., 25: 283, 1993.
37. Wollin, M., Fitzgerald, T. J., Santucci, M. A., Menon, M., Longcope, C., Reale, F., Carlson, J., Sakakeeny, M. A. and Greenberger, J. S.: Radiosensitivity of human prostate cancer and malignant melanoma cell lines. Radiother. Oncol., 15: 285, 1989.
38. Smalley, S. R., Kimler, B. F. and Evans, R. G.: 5-fluorouracil modulation of radiosenstivity in cultured human carcinoma cells. Int. J. Rad. Onc. Biol. Phys., 20: 207, 1991.
39. Kaller, I., Wase, J. L., Wilson, J. D. and Koontz, W. W.: Effect of radiation combined with hyperthermia on human prostatic carcinoma cell lines in culture. Urology, 38: 88, 1991.
40. Jones, S. E., Fuks, Z., Kaplan, H. S. and Rosenberg, S. A.: Non-Hodgkin's lymphoma, V.: Results of radiotherapy. Cancer, 32: 682, 1973.
41. Leeper, D. B., Schneiderman, M. H. and Dewey, W. C.: Radiation-induced cycle delay in synchronized Chinese hamster cells: comparison between DNA synthesis and division. Radiation Res., 53: 326, 1973.
42. Tolmach, L. J., Jones, R. W. and Busse, P. M.: The action of caffeine on X-irradiated HeLa cells. I. Delayed inhibition of DNA synthesis. Radiation Res., 71: 653, 1977.
43. Pilepich, M. V., Krall, J. M., Al-Sarraf, M., John, M. J., Doggett, R. L. S., Sause, W. T., Lawton, C. A., Abrams, R. A., Rotman, M., Rubin, P., Shipley, W. U., Grignon, D., Caplan, R. and Cox, J. D.: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma- a randomized comparative trial of the Radiation Therapy Oncology Group. Urology, 45: 616, 1995.
44. D'Amico, A. V. and Coleman, C. N.: Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J. Clin. Oncol., 14: 304, 1996.
45. Porter, A. T., Blasko, J. C., Grimm, J. D., Reddy, S. M. and Ragde, H.: Brachytherapy for prostate cancer. CA Cancer J. Clin., 45: 165, 1995.
46. Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Shang, Y., Barrett, J. C., Kolodner, R. D. and Kunkel, T. A.: Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res., 55: 6063, 1995.
47. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A. and Boland, C. R.: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res., 54: 4308, 1994.
48. 2 cell cycle checkpoint. Cancer Res., 55: 3721, 1995.
49. Girinsky, T., Koumenis, C., Graeber, T. G., Peehl, D. M. and Giaccia, A. J.: Attentuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA damaging agents. Cancer Res., 55: 3726, 1995.
50. Stattin, P., Damber, J.-E., Modig, H. and Bergh, A.: Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patents. Int. J. Rad. Oncol. Biol. Phys., 35: 885, 1996.
51. Haimovitz-Friedman, A., Kan, C. C., Ehleiter, D., Perraud, R. S., McLoughlin, M., Fuks, Z. and Kolesnick, R. N.: Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med., 180: 525, 1994.
52. Fowler, J. F.: The linear-quadratic formula and progress in fractionated radiotherapy. Br. J. Radiol., 62: 679, 1989.